Currently Viewing:
Currently Reading
In Light of SPRINT, How to Treat Hypertension?
February 15, 2017 – Mary Caffrey
Trial Results Published for Medtronic's MiniMed 670G
February 13, 2017 – Mary Caffrey
Low Socioeconomic Status Linked to Reduced Life Expectancy
February 12, 2017 – Laura Joszt
Self-Management Interventions Could Improve Outcomes for Low-Income Diabetics
February 10, 2017 – Christina Mattina
This Week in Managed Care: February 10, 2017
February 10, 2017
Air Pollution Tied to Increased Type 2 Diabetes Risk in Latino Children
February 09, 2017 – Mary Caffrey
Gastric Bypass Reversal: Diabetes Can Return, Even if Weight Doesn't
February 08, 2017 – Mary Caffrey
Pivotal Trials Launch for 4 NIH-Funded Artificial Pancreas Projects
February 07, 2017 – Mary Caffrey
Population-Level Weight Maintenance Programs Could Help Prevent Diabetes, Study Finds
February 06, 2017 – Christina Mattina

In Light of SPRINT, How to Treat Hypertension?

Mary Caffrey
An author in JAMA points out some caveats to a ground-breaking trial.
How aggressive should doctors be in treating hypertension? The “consensus” seems ever in flux, as new studies emerge. Aram V. Chobanian, MD, of Boston University Medical Center, offered a viewpoint in the current issue of JAMA that takes another look at this question in light of results from SPRINT, the Systolic Blood Pressure Intervention Trial, which upended years of thinking about the benefits of treating older patients with some health risks. Some called SPRINT the most important cardiovascular trial in 40 years.

SPRINT examined the benefit of getting these patients to a goal of having their systolic blood pressure (BP) to 120 mm Hg, and found that in general, it took 1 additional drug to get patients to this goal. The benefits that emerged were so apparent that the National Institutes of Health stopped the trial early. The group being treated aggressively had 25% fewer deaths and 30% fewer cardiovascular events. 

Chobianian noted that the exclusion criteria of SPRINT were such that primary care physicians—who provide the vast majority of care to this population—should take this knowledge into account. And, because of the early end to the trial for ethical reasons, “the full effect of the benefits and adverse events of long-term therapy is unknown.” Of note, he wrote, BP measurements in SPRINT were made after a short period of rest, which is not typical in clinical practice settings.

So, what to do with treatment guidelines? Chobanian offers a recommendation to treat those without high health risk to <120/80 mm Hg up to age 50, and then to treat those between age 50 and 74 to a systolic BP of <130 mm Hg. After age 75, the systolic BP should be <140 mm Hg If the patient has type 2 diabetes, the systolic BP goal should be <140 mm Hg.

“Treatment decisions should continue to be guided by the actual BP values, although other factors need to be considered,” Chobanian wrote. Patients will keep arriving, and as doctors know, “treatment decisions and recommendations may be required even when the evidence base is not conclusive.”

What’s more important, he said, is for doctors to emphasize the need for healthy lifestyles for those in the 130-139/80-85 mm Hg range.


Chobanian AV. Hypertension in 2017—what is the right range? JAMA. 2017; 317(6):579-580. doi:10.1001/jama.2017.0105.


Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up